579 related articles for article (PubMed ID: 30361418)
1. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.
Angelova E; Audette C; Kovtun Y; Daver N; Wang SA; Pierce S; Konoplev SN; Khogeer H; Jorgensen JL; Konopleva M; Zweidler-McKay PA; Medeiros LJ; Kantarjian HM; Jabbour EJ; Khoury JD
Haematologica; 2019 Apr; 104(4):749-755. PubMed ID: 30361418
[TBL] [Abstract][Full Text] [Related]
2. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.
Kovtun Y; Jones GE; Adams S; Harvey L; Audette CA; Wilhelm A; Bai C; Rui L; Laleau R; Liu F; Ab O; Setiady Y; Yoder NC; Goldmacher VS; Chari RVJ; Pinkas J; Chittenden T
Blood Adv; 2018 Apr; 2(8):848-858. PubMed ID: 29661755
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-3 receptor α chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy.
Du W; Li J; Liu W; He Y; Yao J; Liu Y; Lin J; Zheng J
Tumour Biol; 2016 Mar; 37(3):3817-21. PubMed ID: 26474588
[TBL] [Abstract][Full Text] [Related]
4. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping.
Bras AE; de Haas V; van Stigt A; Jongen-Lavrencic M; Beverloo HB; Te Marvelde JG; Zwaan CM; van Dongen JJM; Leusen JHW; van der Velden VHJ
Cytometry B Clin Cytom; 2019 Mar; 96(2):134-142. PubMed ID: 30450744
[TBL] [Abstract][Full Text] [Related]
5. A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML.
Das N; Gupta R; Gupta SK; Bakhshi S; Malhotra A; Rai S; Singh S; Prajapati VK; Sahoo RK; Gogia A; Sharma A; Kumar L
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e673-e684. PubMed ID: 32561191
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia.
Djokic M; Björklund E; Blennow E; Mazur J; Söderhäll S; Porwit A
Haematologica; 2009 Jul; 94(7):1016-9. PubMed ID: 19454491
[TBL] [Abstract][Full Text] [Related]
7. Significance of CD34/CD123 expression in detection of minimal residual disease in B-ACUTE lymphoblastic leukemia in children.
Zeidan MA; Kamal HM; El Shabrawy DA; Esh AM; Sattar RH
Blood Cells Mol Dis; 2016 Jul; 59():113-8. PubMed ID: 27282579
[TBL] [Abstract][Full Text] [Related]
8. CD123 Expression in Philadelphia Chromosome-like B Acute Lymphoblastic Leukemia/Lymphoma.
Lyapichev KA; Sukswai N; Angelova E; Kersh MJ; Pierce S; Konopleva M; Jain N; Jabbour EJ; Jorgensen JL; Wang SA; Medeiros LJ; Khoury JD; Konoplev S
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e317-e320. PubMed ID: 33129747
[No Abstract] [Full Text] [Related]
9. Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia.
Yoshida S; Tuscano E; Duong C; Chung J; Li Y; Beckett L; Tuscano JM; Satake N
Leuk Lymphoma; 2017 May; 58(5):1254-1257. PubMed ID: 27701909
[No Abstract] [Full Text] [Related]
10. CD123 bi-specific antibodies in development in AML: What do we know so far?
Slade MJ; Uy GL
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101219. PubMed ID: 33279175
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
Habibi-Anbouhi M; Kafi Z; Ghazizadeh L; Kharazi S; Behdani M; Faraji F; Shokrgozar MA
Iran J Allergy Asthma Immunol; 2019 Oct; 18(6):679-687. PubMed ID: 32245312
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
14. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
[TBL] [Abstract][Full Text] [Related]
15. Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia.
Aldoss I; Clark M; Song JY; Pullarkat V
Hum Vaccin Immunother; 2020 Oct; 16(10):2341-2348. PubMed ID: 32692611
[TBL] [Abstract][Full Text] [Related]
16. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.
Ruella M; Barrett DM; Kenderian SS; Shestova O; Hofmann TJ; Perazzelli J; Klichinsky M; Aikawa V; Nazimuddin F; Kozlowski M; Scholler J; Lacey SF; Melenhorst JJ; Morrissette JJ; Christian DA; Hunter CA; Kalos M; Porter DL; June CH; Grupp SA; Gill S
J Clin Invest; 2016 Oct; 126(10):3814-3826. PubMed ID: 27571406
[TBL] [Abstract][Full Text] [Related]
17. [Immunophenotyping of leukemic stem cells and chromosome karyotype characteristics in Uyghur leukemia pediatric patients].
Hailiqiguli N; Yan M
Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):501-4. PubMed ID: 24257300
[TBL] [Abstract][Full Text] [Related]
18. International Consensus Classification of acute lymphoblastic leukemia/lymphoma.
Duffield AS; Mullighan CG; Borowitz MJ
Virchows Arch; 2023 Jan; 482(1):11-26. PubMed ID: 36422706
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotypic portrait of leukemia-associated-phenotype markers in B acute lymphoblastic leukemia.
Boris E; Theron A; Montagnon V; Rouquier N; Almeras M; Moreaux J; Bret C
Cytometry B Clin Cytom; 2024 Jan; 106(1):45-57. PubMed ID: 38037221
[TBL] [Abstract][Full Text] [Related]
20. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.
Malumbres R; Fresquet V; Roman-Gomez J; Bobadilla M; Robles EF; Altobelli GG; Calasanz MJ; Smeland EB; Aznar MA; Agirre X; Martin-Palanco V; Prosper F; Lossos IS; Martinez-Climent JA
Haematologica; 2011 Jul; 96(7):980-6. PubMed ID: 21459790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
